Navigation Links
Resverlogix RVX-208 Second Clinical Trial Demonstrates Success on Key Reverse Cholesterol Transport Markers
Date:9/30/2009

given to CVD patients in combination with statins. ApoA-I therapy has the potential to reduce the overall cost of cardiovascular disease, which is estimated in the U.S. at US $475 billion annually, by 5% to 16%.

Resverlogix is also pleased to announce that it will host a live teleconference today, September 29, 2009 at 1:00 pm Eastern/11:00 am Mountain time. The purpose of the teleconference is to discuss the top line results of this clinical trial. The dial-in numbers for this event are toll free 1-800-319-4610 and international 1-604-638-5340. A link for this webcast is posted onto the homepage of Resverlogix's website and can be accessed from the following address http://services.choruscall.com/links/resverlogix090928.html. The webcast will be available on the Resverlogix website for replay for a period of 45 days after the event.

About RVX-208

RVX-208, a novel small molecule therapeutic that facilitates endogenous ApoA-I production, is positioned to be one of the most promising emerging drugs in the treatment of atherosclerosis. To the Company's knowledge RVX-208 is the only novel small molecule that is specifically designed to increase ApoA-I production and thereby raise HDL levels thus enhancing HDL functionality to augment reverse cholesterol transport (RCT). RCT is a pathway by which accumulated cholesterol is transported from the arterial wall to the liver for excretion, thus preventing atherosclerosis.

About Resverlogix Corp.

Resverlogix Corp. is a leading biotechnology company engaged in the development of novel therapies for important global medical markets with significant unmet needs. The NexVas(TM) PR program is the Company's primary focus which is to develop novel small molecules that enhance ApoA-I. These vital therapies address the grievous burden of atherosclerosis and other important diseases such as Acute Coronary
'/>"/>

Resverlogix Corp.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related biology technology :

1. Resverlogix Phase 1b/2a Study Meets Primary Endpoint
2. Resverlogixs Success in Inflammation Program Results in 2 Patents Filed
3. Resverlogix Provides Quarterly Update
4. Resverlogix Board of Directors Update
5. Resverlogix Advances to Second Arm of Phase 1b/2a Clinical Trial
6. Resverlogix Announces Closing of Debt Redemption
7. Resverlogix Eliminates Sixty Percent of Remaining Debt
8. Resverlogix Issues a Management Statement
9. Resverlogix Board of Directors Update
10. Resverlogix Notice of Conference Call & Webcast
11. Jan Gray Joins Resverlogix Board of Directors
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:11/17/2014)... , Nov. 17, 2014 Soligenix, Inc. ... biopharmaceutical company developing products that address unmet medical ... biodefense, announced today the formation of a Medical ... to the Company as it advances the Phase ... the treatment of cutaneous T-cell lymphoma (CTCL), a ...
(Date:11/15/2014)... MA (PRWEB) November 13, 2014 Collaborative ... announced they were named one of the Boston Globe’s ... the Medium Sized Businesses in Massachusetts to receive the ... honors employers who take care of their most valuable ... awards are presented annually, and are based on an ...
(Date:11/15/2014)... The International Society for Cardiovascular ... society’s Governing Board has grown with the additions ... officer and Dr. Charles Simonton, divisional vice president, ... Mr. Rowe and Dr. Simonton are both medical ... , Dr. Nabil Dib, ISCTR President stated, “We ...
(Date:11/15/2014)... November 14, 2014 The "Operating ... Surgical, Performance), by Application (Perioperative, Preoperative, operating room ... (Web-Based, On-Premise) - Global Forecast to 2019.” defines ... an analysis and forecast of value by product, ... Along with this, the value and volumes of ...
Breaking Biology Technology:Soligenix Announces Formation of Cutaneous T-Cell Lymphoma Medical Advisory Board 2Soligenix Announces Formation of Cutaneous T-Cell Lymphoma Medical Advisory Board 3Soligenix Announces Formation of Cutaneous T-Cell Lymphoma Medical Advisory Board 4Soligenix Announces Formation of Cutaneous T-Cell Lymphoma Medical Advisory Board 5Soligenix Announces Formation of Cutaneous T-Cell Lymphoma Medical Advisory Board 6Collaborative Consulting Honored with Boston Globe Top Places to Work 2014 2International Society for Cardiovascular Translational Research Governing Board Adds Medical Industry Leaders 2Operating Room Management Market Worth $4,551.1 Million by 2019 - New Report by MarketsandMarkets 2Operating Room Management Market Worth $4,551.1 Million by 2019 - New Report by MarketsandMarkets 3Operating Room Management Market Worth $4,551.1 Million by 2019 - New Report by MarketsandMarkets 4
... WA, March 10 /PRNewswire-FirstCall/ - Oncothyreon Inc.,(Nasdaq: ONTY ... the year and quarter ended December 31, 2007. All ... Net loss for the year ended December 31, ... share, compared with $36.4 million, or $2.38,per basic and ...
... (Nasdaq: MNKD ) today issued the following ... is absolutely committed to the continued development of ... small,patient-friendly Medtone(R) inhaler to deliver Technosphere(R) Insulin to,patients ... closely matches the pattern,of insulin secretion seen in ...
... - Dr. Brad Thompson, President,and CEO of Oncolytics ... a,corporate overview of the Company at the BioSquare ... is being held at the Congress Center in,Basel, ... Biotech Inc., Oncolytics is a Calgary-based biotechnology ...
Cached Biology Technology:Oncothyreon reports full year and fourth quarter 2007 financial results 2Oncothyreon reports full year and fourth quarter 2007 financial results 3Oncothyreon reports full year and fourth quarter 2007 financial results 4Oncothyreon reports full year and fourth quarter 2007 financial results 5Oncothyreon reports full year and fourth quarter 2007 financial results 6Oncothyreon reports full year and fourth quarter 2007 financial results 7MannKind Corporation Response to Recent Market Events 2MannKind Corporation Response to Recent Market Events 3MannKind Corporation Response to Recent Market Events 4MannKind Corporation Response to Recent Market Events 5MannKind Corporation Response to Recent Market Events 6Media Advisory - Oncolytics Biotech Inc. to Present at BioSquare 2008 2
(Date:11/4/2014)... November 4, 2014   ... growth   Fuel3D , a developer of ... funding round totaling $6.4 million (£4 million). This funding builds ... earlier this year and paves the way for the commercial ... The funding round was led by Chimera Partners and ...
(Date:11/4/2014)... Lithuania , Nov. 4, 2014   ... technologies, today announced that the latest version of ... in the Ongoing MINEX evaluation organized ... of fingerprint algorithms using the INCITS 378 fingerprint ... mandatory requirement in public tenders in ...
(Date:11/3/2014)... University of Colorado Cancer Center study published ... of Sciences describes the activity of a recently ... 37 or IL-37. It has been known to limit ... the adaptive immune system: IL-37 inhibits the ability of ... , "Knowing this mechanism that underlies IL-37,s effect on ...
Breaking Biology News(10 mins):Fuel3D Secures $6.4 Million in Expansion Funding 2Fuel3D Secures $6.4 Million in Expansion Funding 3Neurotechnology Places Second in Ongoing MINEX Ranking for Fingerprint Matching Algorithms 2Neurotechnology Places Second in Ongoing MINEX Ranking for Fingerprint Matching Algorithms 3PNAS: From HIV to cancer, IL-37 regulates immune system 2
... Vegas, NVCONRAD, a leading reproductive health research organization, will announce ... at the Reproductive Health 2011 Conference in Las Vegas, Nevada. ... implemented at six clinical sites in the U.S. showed that ... similar to traditional diaphragms. In addition, SILCS was ...
... -- Decreasing expression of a protein associated with susceptibility ... while improving their hormonal response to stress, a study ... found. The lack of this protein, FKBP51, did not ... The study suggests that drug discovery efforts aimed ...
... MD The Federation of American Societies for Experimental ... client, the Histochemical Society (HCS). The executive leadership ... include general management support, membership marketing, recruitment, and retention, ... Executive Director of HCS, William Stahl, PhD commented, "HCS ...
Cached Biology News:CONRAD presents results of pivotal contraceptive study at Reproductive Health 2011 2CONRAD presents results of pivotal contraceptive study at Reproductive Health 2011 3Lack of protein FKBP51 in old mice improves resilience to depressive behavior 2
...
... Anti-HMGN2/HMG-17 Immunogen : ... Tris-glycine, pH7.4, 5mg/ml BSA, 0.15M ... the addition of glycerol to ... by immunoblot on acid extracts ...
...
... different human fetal normal tissues are ... upon request. Customers can choose ... set, and pay 70% of the ... P Set products are for research ...
Biology Products: